Kiniksa Pharmaceuticals International (KNSA) Operating Leases (2019 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has reported Operating Leases for 8 consecutive years, with $4.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Leases fell 32.56% year-over-year to $4.9 million; the trailing twelve-month figure through Jun 2026 stood at $4.9 million (down 32.56% YoY), and the FY2025 full-year result was $6.5 million, down 17.2% from the prior year.
• Operating Leases retreated to $4.9 million in Q2 2026 per KNSA's latest filing, from $5.9 million in the prior quarter.
• Across five years, Operating Leases topped out at $11.3 million in Q2 2023 and bottomed at $1.3 million in Q2 2022.
• Historically, Operating Leases has averaged $6.6 million across 5 years, with a median of $7.1 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Operating Leases plunged 63.49% in 2022, then jumped 782.86% in 2023.
• Over 5 years, Operating Leases stood at $2.6 million in 2022, then soared by 282.16% to $10.0 million in 2023, then decreased by 21.42% to $7.9 million in 2024, then slipped by 17.2% to $6.5 million in 2025, then declined by 24.96% to $4.9 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $4.9 million, $5.9 million, and $6.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.